Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance

Herck, Koen Van; Leuridan, Elke; Damme, Pierre Van

doi:10.1136/sti.2006.022111

Cited by 42 publications

(36 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is some evidence that rapid schedules may be cost effective 42 for improving completion 25,43,44 although evidence of long-term immunogenicity in this group is still lacking. 11,45 Vaccine-induced immunity to HBV among anti-HCV and anti-HBc negative participants was associated with a history of incarceration but not with recent NSP attendance or lifetime OST, highlighting important missed opportunities for vaccination in these settings. Those who reported recent receptive syringe sharing were significantly less likely to have evidence of vaccine-induced immunity, which may be an indication of lower health service utilisation and engagement.…”

Section: Discussionmentioning

confidence: 99%

Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney

White

Dore

Lloyd

et al. 2012

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney

White

Dore

Lloyd

et al. 2012

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

“…Various studies have investigated the protectiveness and the antibody titers of different HBV vaccine schedules in healthy individuals and highrisk patients (12)(13)(14)(15). Grisha et al (14) investigated the antibody response and compared the 0, 1 and 2 months vaccination schedule to the 0, 1 and 6 months schedule.…”

Section: Discussionmentioning

confidence: 99%

Responsiveness of children with celiac disease to different hepatitis B vaccination protocols

Balamtekin

Uslu²,

Baysoy³

et al. 2011

Turk J Gastroenterol

View full text Add to dashboard Cite

Celiac disease (CD) is a common autoimmune disease characterized by permanent intolerance to ingested gluten, which results in immune-mediated injury of the small bowel mucosa. Genetic, environmental and immunological factors are responsible for the disease. Susceptibility to CD is determined, in part, by a common human leukocyte antigen (HLA) association; specifically, the major histocompatibility complex class II antigen DQ2, which is present in 86% to 100% of the patients (1).Hepatitis B virus (HBV) infection is one of the most important public health problems worldwide. HBV infection acquired during the perinatal, infancy and early childhood periods is a major cause of chronic liver disease and liver cancer (2). Hepatitis B vaccine is highly effective and safe, and it can prevent the morbidity and occasional mortality associated with infection (3). For this reason, HBV vaccine is considered as the main strategy in the control of the infection and viral transmission. HBV vaccine was introduced into clinical practice

show abstract

“…Efficacy of the influenza vaccine is expected to be between 70-90% in young individuals but is considerably reduced to between 30-40% in those over the age of 65 [6,[11][12][13]. A similar story exists with Hepatitis B where an antibody titre of anti-HBs level 10 IU/L following vaccination provides protection [14]. Comparing efficacy of hepatitis B vaccination between healthy elderly individuals (average age 74) versus young control group (average age 28), all of the young individuals developed a protective response, compared with only 42% of the elderly cohort [15].…”

Section: Who?mentioning

confidence: 99%

Immunotherapy of Immunosenesence; Who, How and When?

Govind

Lapenna

Lang

et al. 2012

TOLSJ

View full text Add to dashboard Cite

Major changes in social welfare, economic conditions and medical knowledge over the last 60 years have produced a demographic shift in the population. More individuals are living longer, and in a decade there will be more people over 65 than infants under 5 for the first time in history. Taking the analysis beyond mere numbers reveals that older individuals are now physically more active than their forebears and travel more widely. This provides a greater opportunity for encountering infectious agents which could present a considerable problem. Older individuals are more susceptible to infection and do not respond as well as younger people to vaccination because of an age related decline in immunity, a state which has been termed immunosenesence. This decline is not uniform and some older individuals show a greater decline in their immune response than others. In this review we have sought to consider who are the 'at risk' individuals, how they might best be treated and when.

show abstract

Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance

Cited by 42 publications

References 47 publications

Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney

Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney

Responsiveness of children with celiac disease to different hepatitis B vaccination protocols

Immunotherapy of Immunosenesence; Who, How and When?

Contact Info

Product

Resources

About